Vaxart, inc. VXRT.US Overview
VXRT AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
VXRT Current Performance
-3.84%
Vaxart, inc.
-0.34%
Avg of Sector
-1.60%
S&P500
VXRT Key Information
VXRT Revenue by Segments
Browsing restrictions can be lifted for a fee.
VXRT Net Income
Browsing restrictions can be lifted for a fee.
VXRT Cash Flow
Browsing restrictions can be lifted for a fee.
VXRT Profit Margin
Browsing restrictions can be lifted for a fee.
VXRT PE Ratio River
Browsing restrictions can be lifted for a fee.
VXRT Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
VXRT Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
VXRT Profile
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Price of VXRT
VXRT FAQ
When is VXRT's latest earnings report released?
The most recent financial report for Vaxart, inc. (VXRT) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VXRT's short-term business performance and financial health. For the latest updates on VXRT's earnings releases, visit this page regularly.
What is the operating profit of VXRT?
According to the latest financial report, Vaxart, inc. (VXRT) reported an Operating Profit of -14.94M with an Operating Margin of -71.54% this period, representing a growth of 37.95% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is VXRT's revenue growth?
In the latest financial report, Vaxart, inc. (VXRT) announced revenue of 20.88M, with a Year-Over-Year growth rate of 857.18%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does VXRT have?
As of the end of the reporting period, Vaxart, inc. (VXRT) had total debt of 16.83M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does VXRT have?
At the end of the period, Vaxart, inc. (VXRT) held Total Cash and Cash Equivalents of 28.7M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does VXRT go with three margins increasing?
In the latest report, Vaxart, inc. (VXRT) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -71.54%%, and net margin of -74.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VXRT's profit trajectory and future growth potential.
Is VXRT's EPS continuing to grow?
According to the past four quarterly reports, Vaxart, inc. (VXRT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of VXRT?
Vaxart, inc. (VXRT)'s Free Cash Flow (FCF) for the period is -9.73M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 54.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.